Genus is developing cancer drugs and is currently conducting Phase 2 clinical trials in AML and Multiple Myeloma. Prior to Genus, Mr. Thompson was President, CEO, Director, and Founder of Immtech Pharmaceuticals (AMEX:IMM), from 1992 to 2006, a company developing new medicines for infectious diseases, including working with the Gates Foundation to develop several new drugs for the developing world. Mr. Thompson joined Immtech from Amersham International, where he served from 1985 to 1992.as Divisional Chief Executive Officer, reporting to the Chairman, he was responsible for Amersham Corporation’s Life Sciences, Radiopharmaceuticals, Diagnostics, Quality and Safety Products Divisions, and was a member of the Executive Committee. Amersham was acquired by GE in 2004 for $9.5 billion. Prior to Amersham, Mr. Thompson was a General Manager of the Hepatitis and Infectious Disease and Immunology Business Units at Abbott Laboratories. Mr. Thompson worked for Baxter International from 1981 to 1985, he was Group Marketing Manager for the Hyland Division. In addition, he is a founding member of the Executive Board of the Illinois Bio-technology Industry Association (iBIO).He was a member of the Pharmaceutical Advisory Board for the Gates Foundation. In 1994, Mr. Thompson was a Founder of Xcyte Therapies in Seattle, which developed therapeutic products that enhance the body’s natural immune responses to treat cancer, infectious diseases, and other medical conditions associated with weakened immune systems; Xcyte was merged with Cyclacel Pharma in 2006. Mr. Thompson holds a B.S. from the University of Cincinnati and an M.B.A. from Harvard University.